Locally Advanced Pancreatic Cancer Market to Evolve Rapidly Over the Next Decade by 2032, DelveInsight Observes

DelveInsight's "Locally Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Locally Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Locally Advanced Pancreatic Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Locally Advanced Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Locally Advanced Pancreatic Cancer Market Forecast
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Locally Advanced Pancreatic Cancer Market Report:
• The Locally Advanced Pancreatic Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In November 2025, BetaGlue® Therapeutics ("BetaGlue"), a clinical-stage oncology company advancing a novel radiotherapy platform for targeted solid tumor treatment, announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Application for YntraDoseTM in patients with unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC). This early feasibility study will evaluate the safety and performance of YntraDoseTM in individuals with unresectable LA-PDAC. The condition continues to represent a major health challenge with limited treatment options. Notably, the incidence of LA-PDAC has been rising by about 1.0% annually since the late 1990s and is projected to become the second-leading cause of cancer-related deaths by 2030.
• In February 2025, Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the alpha-radiation cancer therapy Alpha DaRT®, announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement. This approval expands the previously announced IDE from January 27, 2025, which authorized a clinical study evaluating Alpha DaRT in combination with first-line chemotherapy for 12 patients with newly diagnosed metastatic pancreatic cancer. The expansion allows the trial to include a broader population of pancreatic cancer patients.
• In January 2025, Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the company behind the groundbreaking alpha-radiation cancer therapy Alpha DaRT®, has announced promising interim results from multiple clinical studies. These include safety and feasibility trials for pancreatic cancer treatment, a combination study with pembrolizumab for patients with recurrent, unresectable, or metastatic HNSCC, and additional clinical investigations.
• In December 2024, Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that the Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) compared to the control group. The study evaluated the efficacy of Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.
• In advanced Locally Advanced Pancreatic Cancer groups, Cantargia AB's CAN04 in combination with gemcitabine/nab-paclitaxel (PDAC) and gemcitabine/cisplatin had early positive activity
• Aggressive tumour growth and a poor prognosis are two common characteristics of pancreatic cancer. Today, pancreatic cancer affects more than 57,600 Americans annually (and double that figure in Europe)
• According to an article titled "Locally Advanced Pancreatic Cancer" by Osipov et al., approximately four out of five patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease that is initially not amenable to surgery. This is due to the lack of screening options and the ambiguity of symptomatology
• Key Locally Advanced Pancreatic Cancer Companies: AstraZeneca, R-Pharm, Hoffmann-La Roche, AB Science, Meabco A/S, Celgene, iOnctura, Tesaro, Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Eleison Pharmaceuticals, ImmunityBio, Acerta Pharma BV, Salspera LLC, SynerGene Therapeutics, Inc., Merrimack Pharmaceuticals, Rexahn Pharmaceuticals, Inc., and others
• Key Locally Advanced Pancreatic Cancer Therapies: Ixabepilone, Gemcitabine+erlotinib, Masitinib, BP-C1, Gemcitabine, IOA-289, Niraparib, Pamrevlumab, EndoTAG-1 (ET), Fluzoparib, Cirtuvivint, Masitinib, AZD6738, Glufosfamide, PD-L1 t-hank and N-803, ACP-196, Salmonella-IL2, nab-paclitaxel, MM-398, RX-0201 plus Gemcitabine, and others
• The Locally Advanced Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Locally Advanced Pancreatic Cancer than females
• The Locally Advanced Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Locally Advanced Pancreatic Cancer pipeline products will significantly revolutionize the Locally Advanced Pancreatic Cancer market dynamics.

Locally Advanced Pancreatic Cancer Overview
Locally Advanced Pancreatic Cancer (LAPC) is a stage of pancreatic cancer where the tumor has grown beyond the pancreas and invaded nearby blood vessels or organs but has not yet spread to distant sites (metastasis). Due to its involvement with critical structures, LAPC is often considered inoperable. Treatment typically includes chemotherapy, radiation therapy, or a combination of both to shrink the tumor, manage symptoms, and potentially make surgical removal possible.

Get a Free sample for the Locally Advanced Pancreatic Cancer Market Report:
https://www.delveinsight.com/report-store/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Locally Advanced Pancreatic Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Locally Advanced Pancreatic Cancer Epidemiology Segmentation:
The Locally Advanced Pancreatic Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Locally Advanced Pancreatic Cancer
• Prevalent Cases of Locally Advanced Pancreatic Cancer by severity
• Gender-specific Prevalence of Locally Advanced Pancreatic Cancer
• Diagnosed Cases of Episodic and Chronic Locally Advanced Pancreatic Cancer

Download the report to understand which factors are driving Locally Advanced Pancreatic Cancer epidemiology trends @ Locally Advanced Pancreatic Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Locally Advanced Pancreatic Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Locally Advanced Pancreatic Cancer market or expected to get launched during the study period. The analysis covers Locally Advanced Pancreatic Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Locally Advanced Pancreatic Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Locally Advanced Pancreatic Cancer Therapies and Key Companies
• Ixabepilone: R-Pharm
• Gemcitabine+erlotinib: Hoffmann-La Roche
• Masitinib: AB Science
• BP-C1: Meabco A/S
• Gemcitabine: Celgene
• IOA-289: iOnctura
• Niraparib: Tesaro, Inc.
• Pamrevlumab: FibroGen
• EndoTAG-1 (ET): SynCore Biotechnology
• Fluzoparib: Jiangsu HengRui Medicine
• Cirtuvivint: Biosplice Therapeutics
• Masitinib: AB Science
• AZD6738: AstraZeneca
• Glufosfamide: Eleison Pharmaceuticals
• PD-L1 t-hank and N-803: ImmunityBio
• ACP-196: Acerta Pharma BV
• Salmonella-IL2: Salspera LLC
• nab-paclitaxel: SynerGene Therapeutics, Inc.
• MM-398: Merrimack Pharmaceuticals
• RX-0201 plus Gemcitabine: Rexahn Pharmaceuticals, Inc.

Discover more about therapies set to grab major Locally Advanced Pancreatic Cancer market share @ Locally Advanced Pancreatic Cancer Treatment Market
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Locally Advanced Pancreatic Cancer Market Strengths
• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Locally Advanced Pancreatic Cancer
• Strong pipeline activity

Locally Advanced Pancreatic Cancer Market Opportunities
• Rising incidence of cancer will provide a larger window of opportunity for new treatments
• Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity

Scope of the Locally Advanced Pancreatic Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Locally Advanced Pancreatic Cancer Companies: AstraZeneca, R-Pharm, Hoffmann-La Roche, AB Science, Meabco A/S, Celgene, iOnctura, Tesaro, Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Eleison Pharmaceuticals, ImmunityBio, Acerta Pharma BV, Salspera LLC, SynerGene Therapeutics, Inc., Merrimack Pharmaceuticals, Rexahn Pharmaceuticals, Inc., and others
• Key Locally Advanced Pancreatic Cancer Therapies: Ixabepilone, Gemcitabine+erlotinib, Masitinib, BP-C1, Gemcitabine, IOA-289, Niraparib, Pamrevlumab, EndoTAG-1 (ET), Fluzoparib, Cirtuvivint, Masitinib, AZD6738, Glufosfamide, PD-L1 t-hank and N-803, ACP-196, Salmonella-IL2, nab-paclitaxel, MM-398, RX-0201 plus Gemcitabine, and others
• Locally Advanced Pancreatic Cancer Therapeutic Assessment: Locally Advanced Pancreatic Cancer current marketed and Locally Advanced Pancreatic Cancer emerging therapies
• Locally Advanced Pancreatic Cancer Market Dynamics: Locally Advanced Pancreatic Cancer market drivers and Locally Advanced Pancreatic Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Locally Advanced Pancreatic Cancer Unmet Needs, KOL's views, Analyst's views, Locally Advanced Pancreatic Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.